Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02089685
Recruitment Status : Active, not recruiting
First Posted : March 18, 2014
Last Update Posted : February 16, 2021
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : March 11, 2021
Estimated Study Completion Date : March 11, 2021
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):